Prime Medicine will have non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform. MaxCyte has partnered with Prime, a biotech firm focused on delivering one-time curative gene therapies. Under the terms of the deal, Prime will have access to MaxCyte’s Flow Electroporation technology and ExPERT platform. In return, MaxCyte has confirmed it will receive platform licensing fees and program-related revenue under the terms of the agreement. However, no specific financials have been divulged. “Our proprietary…